This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Groeningen, C. J. Articles by Pinedo, H. M. Search for Related Content PubMed PubMed Citation Articles by van Groeningen, C. J. Articles by Pinedo, H. M.

Altered Pharmacokinetics and Metabolism of CPT-11 in Liver Dysfunction: A Need for Guidelines

Department of Medical Oncology, University Hospital Vrije Universiteit, 1081 HV Amsterdam [C. J. V. G., W. J. F. V. d. V., J. J. B., H. S., H. M. P.], and Department of Gastroenterology, Academic Medical Center, 1105 AZ Amsterdam [K. H.], the Netherlands

Metabolic conversion of CPT-11 is a major route of elimination of this new topoisomerase 1 inhibitor. Presently, recommendations for dose adjustments of CPT-11 in patients with liver dysfunction are lacking. We describe the case of a patient with metastatic colon cancer with liver dysfunction treated with CPT-11 at two different dose levels (100 mg/m² and 30 mg/m², single dose, administered as a 90-min i.v. infusion). The lactones and carboxylates of CPT-11 and SN-38 were determined by high-performance liquid chromatography. SN-38 glucuronide was determined after deglucuronidation. The procedures allowed intrapatient comparison of pharmacokinetics and metabolism of the drug. Severe side effects were encountered, which could be explained by the reduced clearance of CPT-11 and its metabolites. These included neutropenic fever with culture-proven septicemia, thrombocytopenia, somnolence, diarrhea, and signs and symptoms of transient hepatic failure. Our findings offer important data for the further development of guidelines for dose reduction of CPT-11 in patients with liver dysfunction.

This article has been cited by other articles:

				L. J. Schaaf, L. A. Hammond, S. J. Tipping, R. M. Goldberg, R. Goel, J. G. Kuhn, L. L. Miller, L. D. Compton, L. A. Cisar, G. L. Elfring, et al. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin. Cancer Res., June 15, 2006; 12(12): 3782 - 3791. [Abstract] [Full Text] [PDF]

				A. Rogatko, J. S. Babb, H. Wang, M. J. Slifker, and G. R. Hudes Patient Characteristics Compete with Dose as Predictors of Acute Treatment Toxicity in Early Phase Clinical Trials Clin. Cancer Res., July 15, 2004; 10(14): 4645 - 4651. [Abstract] [Full Text] [PDF]

				E. Raymond, V. Boige, S. Faivre, G.-J. Sanderink, O. Rixe, L. Vernillet, C. Jacques, M. Gatineau, M. Ducreux, and J.-P. Armand Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction J. Clin. Oncol., November 1, 2002; 20(21): 4303 - 4312. [Abstract] [Full Text] [PDF]

				R. H.J. Mathijssen, J. Verweij, M. J.A. de Jonge, K. Nooter, G. Stoter, and A. Sparreboom Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations J. Clin. Oncol., January 1, 2002; 20(1): 81 - 87. [Abstract] [Full Text] [PDF]